Figure 7
LPS and BDNF trigger primary microglial proliferation in a manner dependent on A 2A R activation. Cells were exposed to LPS (100 ng/mL) for 6 hours in the presence of BrdU for the last 2 hours. Proliferation was quantified as the number of BrdU-labeled nuclei (red) and expressed as a percentage of the total number of DAPI-labeled nuclei (blue). (A) Representative images illustrating the ability of LPS and BDNF to enhance primary microglial proliferation, an effect prevented by the selective A2AR antagonist, SCH58261 (50 nM) (B). Results are expressed as mean ± SEM of two independent experiments (** P < 0.01, *** P < 0.001, compared with non-treated cells; ·· P < 0.01, · P < 0.05, compared with LPS-treated cells) and 100% represents proliferation of cells that were not exposed to LPS. A2AR, A2A receptor; ADA, adenosine deaminase; BDNF, brain-derived neurotrophic factor; BrdU, 5-bromo-2'-deoxyuridine; LPS, lipopolysaccharide; SEM, standard error of the mean.